USP <800>

USP 800, Hazardous Drugs—Handling in Healthcare Settings, sets minimum standards to protect personnel who receive, compound, dispense, administer, transport, and dispose of hazardous drugs. The chapter is designed to reduce worker exposure, contamination of workspaces and products, and environmental release. It applies to all entities that handle hazardous drugs on the NIOSH list, from hospitals and infusion centers to retail, specialty, and compounding pharmacies.

The chapter’s architecture is practical and comprehensive. It establishes expectations for governance (designated person, policies, training, competencies), facility and engineering controls (containment primary and secondary engineering controls), operational procedures (receiving, labeling, transport, spill response, waste), and quality management (documentation, incident review, medical surveillance). It also requires a site-maintained hazardous drug list and allows a documented Assessment of Risk to tailor controls for certain dosage forms and activities.

While USP is a compendial body rather than a regulator, USP 800 is widely adopted by state boards of pharmacy, accreditation organizations, and health systems as a binding standard. Inspectors expect not only the right equipment but also evidence that day-to-day practices consistently follow written procedures, with training, records, and change control maintained.

USP 800 applies to all healthcare settings and related entities that handle hazardous drugs during any part of their lifecycle: receipt, storage, compounding (sterile and nonsterile), dispensing, administration, transport, spill management, and disposal. The chapter is anchored to the NIOSH List of Hazardous Drugs and expects each facility to maintain a current inventory of hazardous drugs it handles, with corresponding standard operating procedures and controls.

The scope is job-task based as much as it is site-based. Anyone who unpacks, stocks, manipulates, prepares, delivers, administers, cleans, or discards hazardous drugs or contaminated materials is in scope. This includes pharmacy staff, nurses, environmental services personnel, and couriers moving hazardous drugs within the facility. Activities that do not manipulate the dosage form, such as handling intact unit-dose packaged tablets, may be managed under an Assessment of Risk when justified and documented.

Applicability extends to logistical touchpoints. Receiving must prevent breakage and contamination, and storage must segregate antineoplastic hazardous drugs that require manipulation. Waste must be placed in properly labeled containers and directed into compliant hazardous and pharmaceutical waste pathways with clear labeling and custody. Entities must ensure that all contracted services that receive or transport hazardous drugs adhere to appropriate controls.

A maintained hazardous drug list is the backbone of USP 800 compliance. Start with the current NIOSH list, then constrain it to items your facility procures or handles. Group entries by antineoplastic status, reproductive risk, and whether manipulation is required. Account for unit dose, packaging integrity, and whether crushing, splitting, reconstituting, or aerosol-generating tasks occur.

Use a structured Assessment of Risk to justify alternative containment strategies for certain dosage forms and tasks where full engineering controls are not necessary. The Assessment of Risk must be written, approved, and reviewed at least annually and whenever handling changes. It should reflect hazard characteristics, exposure routes, frequency of handling, and the protective effectiveness of selected controls, with clear references to the procedures and training that operationalize them.

Facilities benefit from consistent decision logic. A transparent scoring approach or Risk Matrix can drive repeatable outcomes, while alignment with occupational banding concepts such as Containment (OSEL) Banding helps anchor choices to toxicological potency. Keep versioned approvals and link each determination to SOPs via controlled documents.

• Identify drug, formulation, packaging, and anticipated manipulations for each entry.
• Characterize hazards, exposure routes, handling frequency, and spill potential.
• Define engineering controls, PPE, work practices, and residue controls to be used.
• Reference SOPs, training, and cleaning methods that enforce the Assessment of Risk.
• Document residual risks, justification for any reduced controls, and review cadence.
• Maintain approvals and change history under Document Control within your QMS.

USP 800 relies on containment primary engineering controls (C-PECs) to capture aerosols and vapors at the point of generation, and containment secondary engineering controls (C-SECs) to maintain pressure differentials and air changes in the surrounding rooms. For sterile antineoplastic compounding, a Class II biological safety cabinet or compounding aseptic containment isolator must be placed in an externally vented, negative-pressure buffer room that meets the applicable ISO classifications and air change rates, supported by an anteroom.

For nonsterile compounding, a suitable C-PEC such as a containment ventilated enclosure is required and should be located in a negative-pressure room with defined air exchanges; external venting is preferred and is required for certain devices. Storage of antineoplastic hazardous drugs that require manipulation must be in a dedicated, externally vented, negative-pressure room with at least 12 air changes per hour. Refrigerated antineoplastic hazardous drugs must be kept in a dedicated refrigerator located in that negative-pressure room.

Closed-system drug-transfer devices should be used during compounding when the dosage form allows and must be used during administration of antineoplastic hazardous drugs when feasible. Engineering controls are effective only when supported by proper room pressurization monitoring, filter maintenance, and defined response actions when performance drifts. Sterile compounding activities must also satisfy the environmental and procedural provisions in USP 797.

USP 800 requires appropriate personal protective equipment matched to the task and the agent. Chemotherapy-tested gloves are used for most handling. Gowns must be disposable, low-lint, and have back closures with tight cuffs. Eye and face protection and respiratory protection are selected based on the exposure scenario and spill potential. PPE integrity, donning and doffing technique, and change frequency are specified in SOPs and verified by competency assessments.

Every entity designates a responsible person to oversee compliance, training, environmental maintenance, incident review, and continuous improvement. Competency is not a one-time event; assess at onboarding, after procedural changes, and at set intervals. Documentation must show that staff are trained on both HD hazards and site-specific practices, including transport, priming of lines, and spill response.

Medical surveillance is part of a comprehensive exposure control program. Baseline and periodic evaluations, exposure incident follow-up, and trend analysis help identify patterns and guide preventive actions. Surveillance data should be protected and reviewed to adjust controls. Programs should explicitly link findings back to training, equipment maintenance, and procedural revisions to close the loop.

Operational controls knit together all the moving parts of USP 800. Receiving must isolate and inspect hazardous drugs for damage, wipe or over-bag if contamination is suspected, and route them along predetermined corridors that avoid sterile compounding areas. Storage segregates antineoplastic hazardous drugs that require manipulation, with dedicated shelving, spill containment, and temperature control as needed.

Compounding follows engineering and aseptic standards with work-practice controls that minimize generation of aerosols. Priming of IV administration sets with a nonhazardous fluid is performed in the pharmacy to avoid open-system connections at the bedside. Administration employs closed-system drug-transfer devices for antineoplastics when compatible and adheres to PPE and work-practice constraints that prevent leaks or drips.

Transport uses sealed, labeled, and impact-resistant containers along controlled routes. Pneumatic tubes are avoided for hazardous drugs. Spills trigger defined containment and cleanup with kits staged at risk points, followed by medical evaluation if exposure occurs. Waste is segregated based on hazard and managed through compliant internal and external pathways with documentation and labeling that align to environmental and pharmaceutical waste rules.

• Receiving without isolation, surface inspection, and documentation increases exposure risk; establish a defined pathway with controls documented in Chain of Custody.
• Priming administration sets outside the pharmacy invites open-system exposure; pharmacy-based priming and Traceability records reduce risk.
• Using pneumatic tubes for hazardous drugs is an avoidable failure mode; require hand-carry in sealed, labeled secondary containers.
• Inadequate waste segregation blurs environmental obligations; route by hazard and containerize per Waste Stream Segregation.
• Underestimating residual contamination at counters and bins undermines exposure control; formalize wipe-downs and residue checks.

USP 800 distinguishes four distinct actions for surface control. Deactivation uses agents to render hazardous drug residues less active. Decontamination removes residues from surfaces and equipment. Cleaning removes organic and inorganic material. Disinfection, when needed for sterile areas, kills microbial contaminants on already cleaned surfaces. The sequence and agents must be defined in SOPs, validated for compatibility with surfaces and devices, and performed at prescribed frequencies.

Workflows for cleaning should clearly separate hazardous drug areas from nonhazardous areas, employ dedicated tools, and document lot numbers and contact times for agents. Wipe techniques must address edges, undersides, and high-touch points, not just open work surfaces. Equipment such as C-PEC sashes and grilles require careful removal and cleaning by trained personnel with appropriate PPE.

Environmental wipe sampling is recommended to verify control of residues and to inform continuous improvement. Although no single method detects all drug classes, trending consistent locations on a routine schedule can reveal patterns and drive corrective actions. Results, incidents, and changes trigger focused retraining, equipment maintenance, and SOP updates to prevent recurrence.

USP 800 operates in a network of requirements. Sterile hazardous drug compounding must meet both USP 800 containment provisions and the aseptic processing, environmental monitoring, and beyond-use date expectations in USP 797. OSHA standards inform hazard communication, respiratory protection, and PPE selection, while EPA rules drive waste classification and disposal practices. State board regulations and accreditation bodies often adopt or reinforce these expectations, creating convergent obligations.

The NIOSH list underpins the scope of hazardous drugs, and updates to the list require periodic review of a facility’s hazardous drug inventory and Assessment of Risk. Closed-system drug-transfer devices, while not universally mandated for all tasks, are now an expected standard for administration of antineoplastics when compatible. Contracts with external waste and transport vendors should incorporate USP 800 controls to prevent handoff gaps.

Facilities benefit from formal risk management practices. ICH Q9 provides structure for hazard identification, risk analysis, control selection, communication, and review. Using a consistent methodology aligns pharmacy, nursing, and environmental services, ensuring that changes in one area are reflected in training, equipment maintenance, and procedural documentation across the system.

• USP 797 sets sterile compounding quality and environmental controls that must be met alongside USP 800’s containment expectations; see USP 797.
• OSHA guides hazard communication, PPE, and respiratory protection programs that operationalize exposure prevention.
• EPA rules shape pharmaceutical hazardous waste categorization, labeling, storage time limits, and disposal routing.
• A formal risk program aligned to ICH Q9 Quality Risk Management Readiness supports the Assessment of Risk and change control.

Achieving USP 800 conformity requires consistent execution, traceable documentation, and rapid feedback when conditions change. V5 Ultimate provides a governed environment to author, approve, and distribute USP 800 SOPs, train staff to role-based competencies, and maintain a facility-specific hazardous drug list with linked Assessments of Risk. Integrated incident capture and action tracking make exposure events and near misses visible and correctable.

Operationally, V5 orchestrates high-risk steps with checklists, barcode confirmation, and controlled routing. Receiving and transport steps are enforced with labeling and exception capture. Compounding steps, including CSTDs when required by policy, are documented with time stamps and operator sign-offs. Cleaning tasks record agent lots and contact times, and dashboards trend residue tests, incidents, and retraining events to demonstrate continuous improvement.

During audits, V5 produces complete, time-sequenced records that link SOP revisions, training status, competency demonstrations, and day-to-day execution. This end-to-end traceability shortens inspections and substantiates the Assessment of Risk with real-world evidence that the selected controls are consistently applied and effective.